Randomized Controlled Trial of Rituximab and Cost-Effectiveness Analysis in Treating Fatigue and Oral Dryness in Primary Sjögren's Syndrome.
Simon J BowmanColin C EverettJohn L O'DwyerPaul EmeryCostantino PitzalisWan-Fai NgColin T PeaseElizabeth J PriceNurhan SutcliffeNagui S T GendiFrances C HallSharon P RuddockCatherine FernandezCatherine ReynoldsClaire T HulmeKevin A DaviesChristopher J EdwardsPeter C LanyonRobert J MootsEuthalia RoussouIan P GilesLinda D SharplesMichele BombardieriPublished in: Arthritis & rheumatology (Hoboken, N.J.) (2017)
The results of this study indicate that rituximab is neither clinically effective nor cost-effective in this patient population.